Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IO

- PMLiVE

GSK terminates lung cancer vaccine trial

Unable to identify patients who may benefit from MAGE-A3 immunotherapy

- PMLiVE

Pfizer says Xalkori tops chemo as first line therapy

Superior progression free survival for lung cancer patients

- PMLiVE

NICE set to reject Lilly’s Alimta for new use in lung cancer

Drug deemed not cost-effective use of NHS resources in new indication

- PMLiVE

Lilly’s ramucirumab boosts survival in lung cancer

Late-stage trial backs regulatory prospects

- PMLiVE

Blow to Pfizer as dacomitinib fails in lung cancer trials

Unable to demonstrate improved survival in patients

- PMLiVE

GSK ends muscular dystrophy deal

Terminates rare disease collaboration with Prosensa after trial disappointment

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

- PMLiVE

ECC 2013: Nintedanib data boosts Boehringer’s oncology ambitions

Lung cancer drug shows extended overall survival in adenocarcinoma patients

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

National Institute for Health and Care Excellence NICE logo

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links